中国合理用药探索2025，Vol.22Issue(8)：53-58,6.DOI:10.3969/j.issn.2096-3327.2025.08.007
信迪利单抗联合布地奈德福莫特罗治疗非小细胞肺癌合并慢性阻塞性肺疾病的临床研究
Clinical Study of Sintilimab Combined with Budesonide-Formoterol in the Treatment of Non-Small Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease
摘要
Abstract
Objective:To investigate the clinical efficacy of sintilimab combined with budesonide-formoterol in treating non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary disease(COPD).Methods:A total of 102 patients with NSCLC and COPD admitted to a hospital from February 2022 to September 2023 were selected and divided into the control group and the observation group by random number table method,with 51 patients in each group.Both groups received conventional chemotherapy.The control group was treated with budesonide and formoterol fumarate powder for inhalation(Ⅰ)via inhalation,while the observation group was additionally given sintilimab injection on the basis of the control group's treatment.Short-term efficacy,inflammatory factors[interleukin-8(IL-8),C-reactive protein(CRP),interleukin-2(IL-2),procalcitonin(PCT)],tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125),squamous cell carcinoma associated antigen(SCC-Ag)],immune function indicators(CD4+,CD8+,CD4+/CD8+)and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of the observation group(74.51%)was higher than that of the control group(49.02%,P<0.05).IL-8,CRP,PCT,CEA,CYFRA21-1,CA125,SCC-Ag and CD8+were decreased in both groups,with lower levels in the observation group(P<0.05).IL-2,CD4+and CD4+/CD8+were increased in both groups,with higher levels in the observation group(P<0.05).The total incidence of adverse reactions in the observation group(11.76%)was lower than that in the control group(29.41%,P<0.05).Conclusion:Sintilimab combined with budesonide-formoterol shows significant efficacy in treating NSCLC complicated with COPD,which can improve immune function,alleviate inflammatory responses,and has good safety.关键词
慢性阻塞性肺疾病/非小细胞肺癌/信迪利单抗/布地奈德福莫特罗/C反应蛋白/降钙素原Key words
chronic obstructive pulmonary disease/non-small cell lung cancer/sintilimab/budesonide-formoterol/C-reactive protein/procalcitonin分类
医药卫生引用本文复制引用
代香玲,柳家荣..信迪利单抗联合布地奈德福莫特罗治疗非小细胞肺癌合并慢性阻塞性肺疾病的临床研究[J].中国合理用药探索,2025,22(8):53-58,6.基金项目
河南省医学科技攻关计划项目(LHGJ20220971) （LHGJ20220971）
